Eli Lilly & Co. said Thursday that its Type 2 diabetes drug Mounjaro and its weight-loss and diabetes drug Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion. The drugmaker ...
Diabetes drug Mounjaro and weight-loss/diabetes medicine Zepbound drove a big revenue increase Eli Lilly & Co. said its Type-2 Diabetes drug Mounjaro and weight-loss/diabetes medicine Zepbound ...
Eli Lilly (NYSE:LLY) reported strong Q4 2024 results on Thursday, surpassing Wall Street estimates, driven by a more than twofold increase in sales of its weight loss and diabetes drugs Mounjaro ...
Incretins such as glucagon-like peptide-1, or GLP-1, are used in diabetes and obesity drugs like Eli Lilly's Mounjaro and Zepbound. The stock (LLY) dropped 8.2% in morning trading, enough to make ...
Hosted on MSN6mon
Why the weight-loss drug boom is just the beginningFuelled by blockbuster marvels like Ozempic and Mounjaro, which were developed ... including Wegovy and Zepound. Pharma giants Novo Nordisk and Eli Lilly are leading the charge with these game ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback